ClinicalTrials.gg
RecruitingNCT07164859SOLOPCIUpdated Nov 3, 2026

Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI

A Phase 3 interventional study of short dual antiplatelet therapy (DAPT) duration and Standard DAPT duration in Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI) and Antiplatelet Therapy, sponsored by Vincent ROULE. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Vincent ROULE · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,700
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies in Coronary Artery Disease with a site in France — 28 open to participants now, 44 under way, 6 of them phase 3. Coronary Artery Disease · France.

Planned enrollment
38th of 158
1,700 · median 300
Started
2026
with 6 others
Phase 3
36 of 218
1 open now
Primary completion
2029-10
later than 42 of 43 live
Registered
212th of 218
by date

Among the 218 studies in Coronary Artery Disease with a site in France, this one is the 38th largest by planned enrollment of the 158 interventional ones that give a count, is one of 7 that started in 2026, is one of 36 in phase 3, reaches primary completion later than 42 of the 43 other live ones, and was the 212th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

28 of the 218 studies in Coronary Artery Disease with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Coronary Artery Disease with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as the standard DAPT duration (standard treatment regimen) in elderly patients ≥ 65 years.

The main questions it aims to answer are:

Does the reduction of the duration of DAPT reduces rates of bleeding without increasing the risk of cardiovascular events? Researchers will compare a short treatment by DAPT (7 days, followed by single antiplatelet therapy) to a standard treatment duration by DAPT (3 to 12 months) after successful percutaneous coronary intervention with ≥ 1 drug-eluting stent.

Participants will:

  • Take aspirin for 7 days in one group or 3 to 12 months in another group
  • Be contacted by phone at 7 days, 14 days, 21 days, 30 days, 3 months, 6 months and 12 months after hospital discharge
  • Keep a diary of any bleeding or cardiovascular events occurring during the study period
Read the detailed description

While dual antiplatelet therapy (DAPT) is the cornerstone of medical therapy after percutaneous coronary intervention (PCI), its optimal duration is still under debate. DAPT reduces the incidence of thrombotic events but exposes patients to an increased risk of bleeding strongly associated with mortality. Older age is a known predictor of bleeding risk. In the elderly, the duration of DAPT appears to be the most relevant modifiable risk factor.

Bleeding consequences triggered investigations into a further reduction in DAPT duration with the use of the newer generation drug-eluting stent (DES) but none specifically focused on elderly patients. Single antiplatelet therapy (SAPT) using a P2Y12 inhibitor after a short period of DAPT (between 1 and 3 months) has been recently tested in some studies. A meta-analysis focusing on the elderly subgroups (with cut-offs ranging between 65 and 75 years-old) showed similar rates of major bleeding and the composite ischemic endpoint but with a high level of heterogeneity highlighting the need of specific studies in this particular population. A recent large study, including a large proportion of patients ≥ 75 years and comparing SAPT after 1 month of DAPT to DAPT ≥ 3 months, showed a lower incidence of major bleedings while net adverse clinical events and major adverse cardiac events remain non-inferior. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation and inhibition of hemostatic system activation has been reported to be comparable between P2Y12 inhibitor monotherapy and DAPT in healthy subjects. The low thrombogenicity of new coronary devices, potent platelet inhibition with new P2Y12 inhibitors in monotherapy and the potential life-threatening consequences of bleeding which occur mostly in the weeks following PCI support the idea of very short DAPT after PCI in elderly.

The investigators propose a multi-center randomized study to compare the safety and efficacy of very short versus standard-duration DAPT after PCI with DES in elderly patients. The investigators aim to determine whether short DAPT (for 7 days after randomization) followed by SAPT with P2Y12 inhibitor is non inferior to standard-duration DAPT regarding net clinical benefit (a composite of all-cause death, myocardial infarction, stroke, and major bleeding defined by Bleeding Academic Research Consortium (BARC) 3 or 5) at 1 year in elderly patients undergoing PCI for acute or chronic coronary syndrome.

The investigators hypothesized that the very short strategy will be non-inferior to the standard-duration strategy. The very short strategy may allow to further reduce bleedings while maintaining the ischemic risk and may consequently become the default strategy.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Percutaneous Coronary Intervention (PCI)
  • Antiplatelet Therapy
  • Elderly (People Aged 65 or More)

Keywords

  • antiplatelet therapy
  • percutaneous coronary intervention
  • elderly
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 65 years
  • Successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent (final TIMI 3 flow and visually estimated residual diameter stenosis \<30%) for acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina) or chronic coronary syndrome (elective PCI). Inclusion is possible after the last PCI procedure in staged procedure.
  • Randomization must be performed before the discharge from the study site.
  • Written
  • Social security affiliated

Exclusion criteria

Exclusion Criteria:

  • PCI without drug-eluting stent implantation or with a bioresorbable scaffold
  • Planned coronary artery bypass grafting or cardiac surgery
  • Any planned surgery within 12 months unless intended antiplatelet therapy could be maintained throughout the peri-surgical period
  • Index clinical event PCI for stent thrombosis, in-stent restenosis or chronic total occlusion
  • Need for oral anticoagulation therapy
  • Known or allergy to aspirin, clopidogrel, ticagrelor or prasugrel
  • Use of fibrinolytic therapy within 24 hours of PCI
  • Severe renal insufficiency ( \< 30 ml/min/m2) and/or dialysis
  • Increased bleeding risk (prior hemorrhagic stroke; stroke \< 30 days; brain injury\<6 months; history of intracranial tumor or intracranial hemorrhage; internal bleeding\<6 weeks; active bleeding; anemia ( ≤ 8 g/dl) or thrombocytopenia ( \< 100 000 G/L); major surgery\<3 weeks)
  • increased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or drug) or the index clinical event (left main treated, ≥3 stents/treated lesions, total length of stents>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel)
  • less than 1 year
  • Participation in another interventional trial
  • Patients considered as vulnerable by the investigators because of medical, psychological or social conditions:

    • Patients with known or discovered severe cognitive impairment
    • Patients with treated or untreated severe psychological or psychiatric conditions
    • Patients with uncorrected severe hearing or visual handicap
    • Patients with addictive alcohol, drug or substance abuse
    • Patients with protective measures (guardianship, tutorship, curatorship)
    • Any other condition considered by the investigators as not warranting
  • patients with poor quality of the downstream territory with diffuse distal coronary disease
  • women of : non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hysterectomy, bilateral salpingectomy or bilateral oophorectomy-
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,700 participants (estimated)

Study arms

  • Active comparator
    standard DAPT duration

    Patients assigned to standard DAPT duration will receive DAPT (with aspirin and a P2Y12 inhibitor: ticagrelor, prasugrel or clopidogrel for acute coronary syndrome, or clopidogrel for chronic coronary syndrome) for at least 3 months after randomization or longer and followed by single antiplatelet therapy (aspirin or P2Y12 inhibitor, at the discretion of the local investigator after PCI)

    Drug: Standard DAPT duration

  • Experimental
    short DAPT

    Patients assigned to short DAPT will receive DAPT (with aspirin and a P2Y12 inhibitor: ticagrelor, prasugrel or clopidogrel for acute coronary syndrome, or clopidogrel for chronic coronary syndrome) for 7 days (after randomization) followed by P2Y12 inhibitor alone (ticagrelor, prasugrel or clopidogrel as indicated) for 12 months

    Drug: short dual antiplatelet therapy (DAPT) duration

Interventions

06

What researchers measure

Primary outcomes

  1. net clinical benefit

    composite of all-cause death, myocardial infarction, stroke and major bleeding BARC 3 or 5

    Time frame: 12 months after randomization

Secondary outcomes

  1. Major or clinically relevant non-major bleeding

    Major or clinically relevant non-major bleeding (BARC 2, 3 or 5), non inferiority of the experimental arm tested

    Time frame: 12 months

  2. Major or clinically relevant non-major bleeding

    Major or clinically relevant non-major bleeding (BARC 2, 3 or 5), superiority of the experimental arm tested

    Time frame: 12 months

  3. Major cardiovascular and cerebrovascular events

    a composite of all-cause death, myocardial infarction and stroke, non inferiority of the experimental arm tested

    Time frame: 12 months

  4. Major bleeding (BARC 3 or 5)

    Major bleeding (BARC 3 or 5), superiority of the experimental arm tested

    Time frame: 12 months

Other outcomes

  1. net clinical benefit

    a composite of all-cause death, myocardial infarction, stroke, and major bleeding defined as BARC grade 3 or 5, evaluated as superior or not

    Time frame: 12 months

  2. all-cause death

    Time frame: 12 months

  3. myocardial infarction

    myocardial infarction type 1, 3 or 4b based on the universal definition

    Time frame: 12 months

  4. Any stroke

    Any stroke rates, defined by NeuroARC types 1.a, .b, .c, .d or 1.a.H or 3.a

    Time frame: 12 months

  5. Intracranial bleeding

    Intracranial bleeding rates defined by NeuroARC type 1.a.H, 1.b, 1.c hemorrhagic CNS injury

    Time frame: 12 months

  6. cardiovascular death

    Death of cardiovascular cause (according to ARC-2 definition)

    Time frame: 12 months

  7. stent thrombosis

    stent thrombosis rates (definite or probable, ARC-2 definition)

    Time frame: 12 months

  8. All-cause hospitalization

    hospitalization for any cause, lasting ≥ 24h from the admission to the hospital

    Time frame: 12 months

  9. Urgent/unplanned symptoms-driven coronary revascularization

    Unstable angina leading to coronary revascularization (with percutaneous coronary intervention or coronary artery bypass grafting)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2029, 43 months after the start.

Of 62 phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 43 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Mar 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 10, 2025
StartActual
Mar 3, 2026was Oct 2025
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
Caen University Hospital is now Recruiting
Nov 3, 2026
Start date
Oct 2025→Mar 3, 2026 (actual)
Nov 3, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedIndex clinical event PCI for stent thrombosis, in-stent restenosis or chronic total occlusion
  • Editedincreased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or immunosuppressive drug) or the procedureindex clinical event (left main treated, ≥3 stents/treated lesions, total length of stents>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    Caen University Hospital is now Recruiting
    Start date Oct 2025→Mar 3, 2026 (now actual)
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedIndex clinical event PCI for stent thrombosis, in-stent restenosis or chronic total occlusion
    • Editedincreased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or immunosuppressive drug) or the procedureindex clinical event (left main treated, ≥3 stents/treated lesions, total length of stents>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07164859
Lead sponsor
Vincent ROULE
Responsible party
Vincent ROULE (Principal Investigator, University Hospital, Caen) — Sponsor-investigator
First posted
Sep 10, 2025
Start date
Mar 3, 2026
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Vincent ROULE, MD, PhD
Contact
roule-v@chu-caen.fr
+33231063975
Elsa LE BLANC, PhD
Contact
leblanc-e@chu-caen.fr
+33231065135
Vincent ROULE, MD, PhD
principal investigator · University Hospital, Caen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diaminohydroxypropanetetraacetic acid

Start the discussion